Conditions · Blood clot history · 100% virtual
Hormone therapy after a blood clot: why 'never' and 'sure' are both wrong
The short answer
A history of DVT or PE makes the route decisive, not the conversation impossible. Oral estrogen raises clot risk and is generally avoided after a clot. Transdermal estradiol shows little to no added clot risk in observational studies — so for some women, carefully selected options remain, often with hematology input. And if hormones aren't wise for you, real non-hormonal treatments exist.
Medically reviewed by Dr. Zuleikha Tyebjee, MD, Board-Certified Family Medicine · Reviewed August 11, 2026
Why the route through your body matters this much
Estrogen taken as a pill passes through the liver first, where it shifts production of clotting proteins — that's the mechanism behind oral estrogen's increased clot risk, and after a DVT or PE it's why oral estrogen is generally off the table. Estradiol through the skin — a patch or gel — enters the bloodstream directly, skipping that first pass. In large observational studies, standard-dose transdermal estradiol has shown little to no added clot risk, including in higher-risk women.
That distinction is exactly what cookie-cutter clinics miss in both directions. Some hand every woman the same product with no clotting history taken at all — genuinely dangerous with your history. Others hear "blood clot" and end the conversation forever, leaving you with disabling symptoms and no plan. Neither is an evaluation. Your specifics decide: when the clot happened, why, whether it was provoked by surgery or travel or pregnancy, whether you have a diagnosed clotting disorder, and whether you're on anticoagulation now.
Two more honest notes. The progestogen matters too — micronized progesterone appears more favorable on clot risk than some synthetic progestogens in observational data. And sometimes the right answer genuinely is no hormones — in which case fezolinetant, certain low-dose antidepressants, gabapentin, and CBT-based approaches are real, prescribable treatments for symptoms, not consolation prizes. I'll also say plainly when your case needs a hematologist's input before anyone prescribes.
Oral vs. transdermal estrogen after a clot — what the evidence shows
Oral estrogen (tablets)
First pass through the liver shifts clotting-protein production
Transdermal estradiol (patch/gel)
Absorbs through skin directly into the bloodstream — no first pass
Oral estrogen (tablets)
Clearly associated with increased VTE risk in studies
Transdermal estradiol (patch/gel)
Little to no added VTE risk at standard doses in observational studies
Oral estrogen (tablets)
Generally avoided after DVT/PE
Transdermal estradiol (patch/gel)
May remain an option for selected women, often with hematology input
Oral estrogen (tablets)
Risk compounds with clotting disorders
Transdermal estradiol (patch/gel)
Still requires individual assessment — observational evidence, not a guarantee
Oral estrogen (tablets)
Not where I start with your history
Transdermal estradiol (patch/gel)
Where the conversation starts, if hormones are on the table at all
What I weigh before prescribing anything
The story of your clot
A clot provoked by surgery, a long flight, or pregnancy reads differently than an unprovoked one — provoked with a resolved cause sits lower on the risk ladder.
Any diagnosed clotting disorder
Factor V Leiden and other thrombophilias change the math and usually mean a hematologist belongs in the conversation before prescriptions.
Whether you're anticoagulated now
Current anticoagulation changes both the risk picture and the coordination — your prescribing doctors need to be in sync, and I make that happen.
Route, dose, and progestogen choice
If we proceed: transdermal estradiol at the lowest effective dose, with micronized progesterone if a progestogen is needed — each choice made for your history.
The non-hormonal path, taken seriously
Fezolinetant, certain antidepressants at low dose, gabapentin, and CBT have real evidence for symptoms. 'No hormones' never means 'no treatment'.
Questions worth asking any doctor — including me
Bring these to your next appointment, wherever it is. A doctor who welcomes them is a good sign.
- Was my clot provoked or unprovoked — and how does that change my options?
- Should I be tested for a clotting disorder before we discuss hormones at all?
- Why would transdermal estrogen carry different risk than pills in my case?
- Do you want a hematologist's input before prescribing — and if not, why not?
- Which progestogen would you use with my history, and why?
- If hormones aren't wise for me, what exactly is the non-hormonal treatment plan?
Questions I hear about this
I had a DVT five years ago. Is hormone therapy completely off the table?
Not automatically — but it deserves a genuinely careful evaluation, not a quick yes or no. The specifics of your clot, any clotting disorder, and your current health decide. If hormones are considered, it's transdermal estradiol territory, often with hematology input. And if the answer is no, we treat your symptoms other ways.
Why is the patch different from the pill for clot risk?
Oral estrogen is processed by the liver first, which shifts the production of clotting proteins — that's the clot-risk mechanism. Through the skin, estradiol enters the bloodstream without that first pass. In large observational studies, standard-dose transdermal estradiol showed little to no added clot risk, which is why route is the central decision with your history.
What are my options if hormones really aren't wise for me?
Real ones. Fezolinetant, a newer non-hormonal prescription, targets hot flashes directly. Certain antidepressants at low doses, and gabapentin, have solid evidence for vasomotor symptoms. CBT-based approaches help sleep and symptom burden. None of these touch clot risk, and I prescribe them where they fit.
My clot happened during pregnancy. Does that count the same?
Pregnancy is a recognized provoking factor — a clot in that setting, with no trouble since, generally reads lower-risk than an unprovoked clot. It absolutely still counts and shapes the plan, but it's exactly the kind of detail that separates a real evaluation from a blanket 'never'. Testing for an underlying disorder may still be worth discussing.
Sources
- HRT and risk of venous thromboembolism — nested case-control studies — BMJ (Vinogradova et al.), 2019.
- The 2022 hormone therapy position statement — The Menopause Society (formerly NAMS), 2022.
- Menopause: identification and management (NG23) — VTE sections — NICE, 2015 (updated).
- Nonhormone therapy position statement (vasomotor symptoms) — The Menopause Society (formerly NAMS), 2023.
Related here: Migraine with aura — the same route reasoning · High blood pressure — the other vascular question · All conditions I work around
Bring me this history — it's the part of the visit I care about most
One visit, $150, paid after we talk. No subscription, no package — and if I'm not the right physician for your situation, I'll say so.
I'm licensed in 15 states: Alabama, California, Florida, Georgia, Illinois, Indiana, Mississippi, Missouri, New Jersey, New York, Oklahoma, South Carolina, Tennessee, Texas, Washington. Please check yours before booking.
Book a $150 visitNot sure yet? Ask me a question first.